查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
癌症基因治療市場——全球行業規模、份額、趨勢、機會、預測，2018-2028 年，按療法、按適應症、按最終用戶、按地區、競爭
市場調查報告書
商品編碼
1255232

癌症基因治療市場——全球行業規模、份額、趨勢、機會、預測，2018-2028 年，按療法、按適應症、按最終用戶、按地區、競爭

Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Therapy, By Indication, By End User, By Region, and Competition
出版日期: | 出版商: TechSci Research | 英文 113 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球癌症基因治療市場預計在預測期內將出現令人矚目的增長。

隨著人們對低成本、低痛苦治療的需求不斷增加以及人們審美的不斷提高，世界各個地區對癌症基因治療的需求都大大增加。 此外，人們對基因治療和診斷的好處的認識不斷提高，全球癌症治療的醫療保健支出不斷增加，預計將在預測期內進一步推動癌症基因治療市場的發展。 到 2022 年，估計美國將有 66,470 人（48,520 名男性和 17,950 名女性）被診斷出患有頭頸癌。

啟動研發活動

研發活動的增加和醫療保健基礎設施的改善帶來的技術進步是預測期內癌症基因治療市場增長的主要驅動力。 政府機構專注於發達的基礎設施以獲得更高的利潤。 倫理上可接受的癌症治療的各種創新療法和新產品的不斷開發也有望在未來幾年推動市場增長。 預計監管環境的改善將增加對癌症基因治療的需求，並在預測期內推動市場增長。 生產商正在受到監管，以確保發布與消費者健康直接相關的無缺陷產品，這可能會推動未來幾年的市場增長。 基因治療產品的缺陷對患者來說可能是災難性的，並且已經修改了幾項法律以防止在上市後監督期間召回產品。 然而，未來幾年癌症基因治療市場的擴張將得益於高質量癌症基因療法的日益普及。 到 2020 年，估計美國將診斷出 276,480 例浸潤性乳腺癌新病例和 48,530 例原位乳腺癌新病例。

基因治療的不斷進步

預測期間，由於人口增長、過度飲酒、吸煙、低體力活動、高體重指數以及水果和蔬菜攝入量低，糖尿病和肥胖等生活方式相關疾病的患病率將進一步增加期間。預計將在市場上產生有利可圖的增長。 2022 年 3 月，美國國家心肺血液研究所向印第安納大學醫學院的研究人員撥款 1200 萬美元。 這筆贈款旨在開發一種更安全且具有潛在治愈性的基因治療方法的關鍵組成部分，用於治療血友病。 因此，各種私營公司和政府機構正在投資基因療法以治愈世界各地的癌症疾病。 同樣，對實驗室自動化的需求不斷增加以及對預防保健意識的提高一直是推動市場多年來增長的主要因素。 癌症患者人數的增加主要影響了該行業的發展，因為它是世界上第二大死因。 到 2020 年，估計美國將診斷出 1,806,590 例新癌症病例，606,520 例將死於該病。

近期發展

  • 2021 9 月，Adaptimmune 與 Genentech 合作開發了針對多種癌症適應症的同種異體細胞療法。
  • 2021 年 6 月，Eisai和Bristol-Myers Squibb K.K.同意合作開發和商業化衛材的 ADC MORAb-202，用於治療晚期實體惡性腫瘤。底部。
  • 2021 年 6 月 GSK 和 iTeos Therapeutics 合作開發 EOS-448，這是一種抗 TIGIT 單克隆抗體，之前在 Phase 1 階段獲批用於治療晚期實體瘤，與

可自定義

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析。

內容

第 1 章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢

第 4 章 VOC（客戶之聲）

第5章臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成臨床試驗
  • 已完成臨床試驗
  • 管道細分，按開發階段
  • 管道細分，按狀態
  • 按研究類型劃分的管道細分
  • 按地區劃分的渠道細分
  • 臨床試驗熱圖

第6章全球癌症基因治療市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過療法（癌細胞療法、基因引導的免疫療法、基因轉移等）
    • 按適應症（乳腺癌、卵巢癌、肺癌、肝癌、胰腺癌、前列腺癌等）
    • 最終用戶（生物技術/製藥公司、學術/研究機構等）
    • 按地區
    • 按公司分類（2022 年）
  • 市場地圖

第7章北美癌症基因治療市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過治療
    • 根據指示
    • 最終用戶
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 加拿大
    • 墨西哥

第8章歐洲癌症基因治療市場前景

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過治療
    • 根據指示
    • 最終用戶
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第9章亞太癌症基因治療市場前景

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過治療
    • 根據指示
    • 最終用戶
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第 10 章南美癌症基因治療市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過治療
    • 根據指示
    • 最終用戶
    • 按國家
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章中東和非洲癌症基因治療市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 通過治療
    • 根據指示
    • 最終用戶
    • 按國家
  • MEA：國家分析
    • 南非的癌症基因治療
    • 沙特阿拉伯的癌症基因治療
    • 阿聯酋的癌症基因治療

第 12 章市場動態

  • 司機
  • 任務

第13章市場趨勢與發展

  • 近期趨勢
  • 併購
  • 產品公告

第14章競爭格局

  • Abeona Therapeutics Inc.
  • Asklepios BioPharmaceutical Inc.
  • Altor Bioscience Inc.
  • Bluebird bio-Inc.
  • BioCancell Inc.
  • Celgene Inc.
  • Elevate Bio Inc.
  • GlaxoSmithKline Inc.
  • Genelux Corporation
  • Introgen Therapeutics Inc.
  • OncoGenex Pharmaceuticals Inc.
  • Merck KGaA

第 15 章戰略建議

簡介目錄
Product Code: 14340

The Global Cancer Gene Therapy Market is anticipated to witness impressive growth during the forecast period. Growing demand for painless treatment at lower cost coupled with increasing aesthetic consciousness among the population significantly increases the demand for cancer gene therapy across different parts of the globe. Besides, growing awareness about the advantages of using gene therapy and diagnosis, along with increasing healthcare expenditure on cancer treatment across the globe, is further expected to support the Cancer Gene Therapy Market during the forecast period. In 2022, an estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States.

Increasing research and development activities

Increasing research and development activities and technological advancement with developed healthcare infrastructure is the major factor for the growth of the cancer gene therapy market during the forecast period. Government organizations are focusing on developed infrastructure with higher profit. Different type of innovative therapies is available for cancer therapy which is ethically acceptable, and the increasing development of new products are expected to boost the market growth over the years. The growing regulatory environment has enhanced the demand for cancer gene therapy which will boost market growth during the forecast period. Due to their direct connection to consumer health, regulations are placed on producers to assure the release of products that are free from flaws which can drive market growth over the years. Some laws have been changed to prevent product recalls during post-marketing surveillance since any flaws in gene therapy goods could be disastrous for patients. However, the expansion of the cancer gene therapy market in the years to come will be aided by the growing availability of high-quality cancer gene therapy. In 2020, an estimated 276,480 new cases of invasive breast cancer will be diagnosed in women in the U.S. as well as 48,530 new cases of non-invasive (in situ) breast cancer.

Growing advancement in gene therapy

The increasing prevalence rate of lifestyle disorders such as diabetes and obesity, excessive alcohol consumption, tobacco use, low physical activity, high body mass index, and low intake of fruits and vegetables because of the growing population is further expected to create a lucrative growth of the market during the forecast period. In march 2022, the National Heart, Lung, and Blood Institute granted USD 12 million to an Indiana University School of Medicine Researcher. This grant is for developing a major part of a gene therapy approach to safer and potentially curative treatments for hemophilia diseases. So different private and government organizations are investing in gene therapy for curing cancer diseases across the globe. Similarly, increasing demand for laboratory automation and growing awareness of preventative healthcare are the major factors that will boost the market growth over the years. The rise in cancer cases is primarily affecting the growth of the industry, being the second largest death cause in the world. In 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States, and 606,520 people will die from the disease.

Market Segmentation

The Global Cancer Gene Therapy Market can be segmented by therapy, indication, end user, and by region. Based on therapy, the market can be segmented into Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others. Based on indication, the market can be segmented into Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, and Others. Based on the end user, the market can be differentiated by Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, and Others. Regionally, North America dominates the market among Asia Pacific, Europe, Middle East & Africa, and South America. Amongst the different countries, the United States dominates the global cancer gene therapy market on account of the growing demand for advanced therapy with low costs for curing cancer diseases in the country.

Recent Developments

  • In Sept 2021, Adaptimmune collaborated with Genentech to develop allogeneic cell therapies indicated for the treatment of multiple cancers.
  • In June 2021, Eisai and Bristol Myers Squibb agreed to partner for the development and commercialization of Eisai's ADC, MORAb-202, for the treatment of advanced solid malignancies.
  • In June 2021, GSK and iTeos Therapeutics partnered to develop EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for the treatment of advanced solid malignancies.

Market Players

Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio-Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, Introgen Therapeutics Inc., OncoGenex Pharmaceuticals Inc., Merck KGaA are some of the leading players operating in the Global Cancer Gene Therapy Market.

Report Scope

In this report, global cancer gene therapy systems market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Cancer Gene Therapy Market, By Therapy:

  • Oncolytic Virotherapy
  • Gene Induced Immunotherapy
  • Gene Transfer
  • Others

Cancer Gene Therapy Market, By Indication:

  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Others

Cancer Gene Therapy Market, By End User:

  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutions
  • Others

Cancer Gene Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Cancer Gene Therapy Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Cancer Gene Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, Others)
    • 6.2.2. By Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, Others)
    • 6.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Market Map

7. North America Cancer Gene Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Indication
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Cancer Gene Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End User
    • 7.3.2. Canada Cancer Gene Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End User
    • 7.3.3. Mexico Cancer Gene Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End User

8. Europe Cancer Gene Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Cancer Gene Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Cancer Gene Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Cancer Gene Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Cancer Gene Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Cancer Gene Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By End User

9. Asia-Pacific Cancer Gene Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Cancer Gene Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End User
    • 9.3.2. India Cancer Gene Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End User
    • 9.3.3. Japan Cancer Gene Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End User
    • 9.3.4. South Korea Cancer Gene Therapy Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapy
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By End User
    • 9.3.5. Australia Cancer Gene Therapy Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapy
        • 9.3.5.2.2. By Indication
        • 9.3.5.2.3. By End User

10. South America Cancer Gene Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Gene Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Cancer Gene Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Cancer Gene Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End User

11. Middle East and Africa Cancer Gene Therapy Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy
    • 11.2.2. By Indication
    • 11.2.3. By End User
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Cancer Gene Therapy Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapy
        • 11.3.1.2.2. By Indication
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Cancer Gene Therapy Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapy
        • 11.3.2.2.2. By Indication
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Cancer Gene Therapy Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapy
        • 11.3.3.2.2. By Indication
        • 11.3.3.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Abeona Therapeutics Inc.
    • 14.6.2. Asklepios BioPharmaceutical Inc.
    • 14.6.3. Altor Bioscience Inc.
    • 14.6.4. Bluebird bio-Inc.
    • 14.6.5. BioCancell Inc.
    • 14.6.6. Celgene Inc.
    • 14.6.7. Elevate Bio Inc.
    • 14.6.8. GlaxoSmithKline Inc.
    • 14.6.9. Genelux Corporation
    • 14.6.10. Introgen Therapeutics Inc.
    • 14.6.11. OncoGenex Pharmaceuticals Inc.
    • 14.6.12. Merck KGaA

15. Strategic Recommendations